AstraZeneca/MedImmune
FDA Approves Lumoxiti for Hairy Cell Leukemia
Lumoxiti is a CD22-directed cytotoxin approved to treat adults with relapsed or refractory hairy cell leukemia.
SEPTEMBER 13, 2018

FDA Approves Fasenra for Severe Eosinophilic Asthma
The FDA approved benralizumab for the add-on maintenance treatment of patients with severe eosinophilic phenotype ...
NOVEMBER 15, 2017

Load more